This is a multi-center, prospective,continuous registry study. The investigators will include 3000 young adult (18-45 years old) patients with confirmed first-ever acute ischemic stroke in China. The main purpose of this study is to build the study cohort of young ischemic stroke patients in China, and to compare the prognosis and stroke recurrence of young patients with different ischemic stroke subtypes. Secondary objectives are trying to find biomarkers of stroke recurrence.

Start Date26 Nov 2017

Sponsor / Collaborator

The First Hospital of Jilin University

[+8]

NCT03108716

/ CompletedNot ApplicableIIT

Hamate Hook Removal, Microscrew Internal Fixation and Plaster Fixation for the Treatment of Hamate Hook Fractures: a Case Series

To compare the effects of hamate hook removal, microscrew internal fixation and plaster fixation on fracture healing, work, life, and exercise recovery in patients with hamate hook fractures by retrospective case analysis.

Start Date01 Jan 2011

Sponsor / Collaborator

Siping Central People's Hospital

100 Clinical Results associated with Siping Central People's Hospital

0 Patents (Medical) associated with Siping Central People's Hospital

Literatures (Medical) associated with Siping Central People's Hospital

10 Jan 2025·Anti-Cancer Agents in Medicinal Chemistry

Schisanhenol Inhibits the Proliferation of Hepatocellular Carcinoma Cells by Targeting Programmed Cell Death-ligand 1 via the STAT3 Pathways

Article

Author: Han, Xu ; Yuan, Siyu ; Wang, Chunmei ; Wang, Mengyang ; Wang, Yuhan ; Hu, Xueyang ; Huang, Lei ; Liu, Chang ; Zhong, Yiwen ; Liu, Wei ; Guo, Xin ; Wu, Jiping ; Sun, Jinghui ; Chen, Jianguang ; Li, Ziqing ; Zhuang, Wenyue ; Li, Siying ; zhang, Zhihong ; Li, He

Background::Programmed cell death-ligand 1 (PD-L1) is overexpressed in tumor cells, which promotes tumor cell survival and cell proliferation and causes tumor cells to escape T-cell killing. Schisanhenol, a biphenyl cyclooctene lignin-like compound, was extracted and isolated from the plant named Schisandra rubriflora (Franch.).Purpose:In this work, we studied the anticancer potential of schisanhenol and explored whether schisanhenol mediated its effect by inhibiting the expression of PD-L1 in vitro and in vivo.Materials and Methods:In vitro, we performed western blot, immunofluorescence, immunoprecipitation, and colony formation assays to study the proteins, genes, and pathways related to the anti-tumour activity of schisanhenol. In vivo, we explored the antitumor activity of schisanhenol through orthotopic liver transplantation and subcutaneous transplantation tumor models of hepatocellular carcinoma (HCC) cells.Results:We found that schisanhenol decreased the viability of HCC cells. It inhibited the expression of programmed cell death ligand-1 (PD-L1), which plays a pivotal role in tumorigenesis. Subsequently, schisanhenol suppressed the expression of PD-L1 by decreasing the activation of STAT3. Furthermore, we found that schisanhenol inhibited the activation of STAT3 via JAK/STAT3 (T705), Src/STAT3 (T705), and PI3K/AKT/mTOR/STAT3 (S727) pathways. Colony formation tests showed that schisanhenol suppressed cell proliferation by inhibiting PD-L1. Schisanhenol also enhanced cytotoxic T lymphocytes (CTL) activity and regained their ability to kill tumour cells in co-culture. Finally, in vivo observation confirmed the antitumor activity of schisanhenol.Conclusion:Schisanhenol inhibits the proliferation of HCC cells by targeting PD-L1 via the STAT3 pathways. These findings prove that schisanhenol is a valuable candidate for HCC therapeutics and reveal previously unknown characteristics of schisanhenol.

01 Jan 2025·Stroke

Serum GFAP and UCH-L1 Levels for the Assessment of the Absence of Hemorrhagic Transformation: A Multicenter Prospective Cohort Study

Article

Author: Chen, Li-Ping ; Zheng, Xiang-Yu ; Gu, Yan-Qiu ; Zhang, Yu ; Sun, Xin ; Li, Yang ; Li, Chun-Ying ; Wang, Jing ; Liu, Xiao-Dong ; Jiang, Chun-Li ; Hu, Xue-Feng ; He, Ling ; Wang, Junmin ; Pan, De-Wang ; Zhao, Li-Li ; Nguyen, Thanh N. ; Liu, Li ; Dong, Chen-Peng ; Dong, Yang ; Jiang, Ligang ; Abuduxukuer, Reziya ; Zhang, Xian-Kun ; Wang, Cui ; Ju, Dong-Sheng ; Jiang, Yongfei ; Yang, Yi ; Cheng, Xiao-Ying ; Wang, Chun-Fei ; Guo, Zhen-Ni ; Gao, Jian-Hua ; Xin, Hong ; Liu, Xue ; Liu, Liang ; Wang, An-Ying ; Zhang, Peng ; Chen, Yu-Mei ; Qi, Ying-Bin ; Gu, Ji-Liang ; Chen, Jin-Hua ; Pang, Meng ; Jia, Yan ; Li, Song ; Qi, Shuang ; Wang, Lijuan ; Jin, Hang ; Teng, Rui-Hong ; Yuan, Zhi-Mei ; Qu, Yang ; Zhang, Ke-Jia

BACKGROUND:Currently, validated biomarkers for assessing hemorrhagic transformation (HT) after intravenous thrombolysis (IVT) are lacking. We aimed to validate a test combining GFAP (glial fibrillary acidic protein) and UCH-L1 (ubiquitin C-terminal hydrolase-L1) to indicate the absence of HT after IVT.METHODS:We prospectively enrolled consecutive patients with stroke treated with IVT from 16 hospitals. Serum GFAP and UCH-L1 levels were measured 24 hours after IVT. Cases from 1 hospital were randomly assigned to the training (70%) and testing (30%) cohorts for internal validation. The external validation cohort included patients from the other 15 hospitals. Cutoff levels of GFAP and UCH-L1 for assessing the absence of HT were established in the training cohort and subjected to internal and external verification.RESULTS:A total of 1063 patients were included. Both GFAP and UCH-L1 levels were independently associated with HT, infarct volume, and 3-month outcome; levels lower than cutoff (12.6 and 63.1 pg/mL, respectively) excluded patients with HT with a negative predictive value of 98.31% (95% CI, 89.70%–99.91%) and detection sensitivity of 98.08% (95% CI, 88.42%–99.90%) in the training cohort. In the testing and validation cohorts, negative predictive value was 100% (95% CI, 75.93%–100%) and 100% (95% CI, 82.19%–100%), respectively, and the sensitivity was 100% (95% CI, 80.76%–100%) and 100% (95% CI, 77.08%–100%), respectively.CONCLUSIONS:Serum GFAP and UCH-L1 levels exhibit high sensitivity and negative predictive value for indicating the absence of HT 24 hours after IVT, which supports their potential role in assessing patients’ condition after IVT.

20 Dec 2024·Medicine

Risk prediction models for non-invasive ventilation failure in patients with chronic obstructive pulmonary disease: A systematic review

Review

Author: Gao, Yuming ; Li, Mingtao ; Fan, Peng ; Yuan, Bo ; Chen, Jiarui

Background:Chronic obstructive pulmonary disease (COPD) is a common respiratory condition with high morbidity and mortality. Noninvasive mechanical ventilation (NIV) is often used to manage acute COPD exacerbations, but failure can lead to worse outcomes. This systematic review aimed to evaluate risk prediction models for NIV failure in patients with COPD.Methods:PubMed, Embase, Web of Science, The Cochrane Library, CINAHL, CBM, CNKI, Wanfang, and VIP databases, from database inception to January 10, 2024, were searched for studies on risk prediction models for failure in NIV among COPD patients. Two reviewers independently screened the literature, extracted data, assessed the quality of included studies using the Prediction Model Risk of Bias Assessment Tool, and conducted a systematic evaluation of the prediction models.Results:A total of 11 studies were included, encompassing 13 risk prediction models. The area under the receiver operating characteristic curve for the included models ranged from 0.810 to 0.978. Predictive factors in the models mainly included Acute Physiology And Chronic Health Evaluation II score, pH value, PaCO2, consciousness status, serum albumin level, and respiratory rate.Conclusion:Existing risk prediction models for failure in NIV among patients with COPD demonstrated overall good predictive performance, but exhibited a risk of bias. Further validation is needed to assess the clinical applicability of these models.

100 Deals associated with Siping Central People's Hospital

100 Translational Medicine associated with Siping Central People's Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 30 Apr 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Siping Central People's Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 30 Apr 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing